Absence of theERBB2 kinase domain mutation in lung adenocarcinomas in Korean patients
Open Access
- 11 April 2005
- journal article
- letter
- Published by Wiley in International Journal of Cancer
- Vol. 116 (4) , 652-653
- https://doi.org/10.1002/ijc.21113
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Intragenic ERBB2 kinase mutations in tumoursNature, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Toward Customized Trastuzumab in HER-2/neu-Overexpressing Non-Small-Cell Lung CancersJournal of Clinical Oncology, 2004
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Epidermal growth factor receptor: mechanisms of activation and signallingExperimental Cell Research, 2003
- Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic DiseaseJournal of Clinical Oncology, 1999
- A simple, precise and economical microdissection technique for analysis of genomic DNA from archival tissue sections.Virchows Archiv, 1998
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987